Keryx Share Price Tumbles Sharply On Phase III Failure Of Perifosine
This article was originally published in The Pink Sheet Daily
Executive Summary
With disappointing data in advanced colorectal cancer, Keryx is expected to abandon development of the Akt pathway inhibitor and focus all efforts on Phase III candidate Zerenex in ESRD.